Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Alzheimer's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 8, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
707
Shown on this page
12
Current sort
Recently updated
Condition scope
Alzheimer's Disease
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Alzheimer's Disease studies are organized in the registry

The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Alzheimer's Disease. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 707 matching trials for Alzheimer's Disease.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
Conditions
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Alzheimer s Disease, Mild Cognitive Impairment, Healthy
Interventions
18F-PF974, 18F-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
50 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Fullerton, California • Irvine, California • Los Angeles, California + 28 more
Conditions
Alzheimers Disease
Interventions
No Intervention
Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nutley, New Jersey
Conditions
Early Alzheimer's Disease
Interventions
MK-2214, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
36
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 32 more
Conditions
Alzheimer's Disease
Interventions
Psilocybin, Cognitive Training
Drug · Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF - Combo INI+EMPA Trial

NCT05081219
Conditions
Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
Interventions
Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules)
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Alzheimer's Disease
Interventions
Remternetug, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
123
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 108 more
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
Conditions
Alzheimer s Disease, MCI With Increased Risk for Alzheimer Disease
Interventions
Ultrasonic Debris Clearance, sham
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Recruiting No phase listed Observational Accepts healthy volunteers

Wake Forest Alzheimer's Disease Clinical Core

NCT03140865
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina

About this Alzheimer's Disease clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.